Skip to Main Content

Paper Details

Combination of a proteomics approach and reengineering of meso scale network models for prediction of mode-of-action for tyrosine kinase inhibitors.
PLoS One
5
2013
ABL, BCR, anti, cancer, cells, chronic myeloid leukemia (CML, chronic myeloid leukemia (CML) cell lines, tumor, tyrosine, tyrosine kinase

Datasets

Release 1.2